These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 30758919

  • 41. Pharmacokinetics and pharmacodynamics of tecarfarin, a novel vitamin K antagonist oral anticoagulant.
    Albrecht D, Ellis D, Canafax DM, Combs D, Druzgala P, Milner PG, Midei MG.
    Thromb Haemost; 2017 Apr 03; 117(4):706-717. PubMed ID: 28180234
    [Abstract] [Full Text] [Related]

  • 42. Effect of tecarfarin, a novel vitamin K epoxide reductase inhibitor, on coagulation in beagle dogs.
    Choppin A, Irwin I, Lach L, McDonald MG, Rettie AE, Shao L, Becker C, Palme MP, Paliard X, Bowersox S, Dennis DM, Druzgala P.
    Br J Pharmacol; 2009 Nov 03; 158(6):1536-47. PubMed ID: 19845677
    [Abstract] [Full Text] [Related]

  • 43. Pharmacodynamics and pharmacokinetics during the transition from warfarin to rivaroxaban: a randomized study in healthy subjects.
    Kubitza D, Becka M, Mück W, Krätzschmar J.
    Br J Clin Pharmacol; 2014 Aug 03; 78(2):353-63. PubMed ID: 24528331
    [Abstract] [Full Text] [Related]

  • 44. Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol.
    Ufer M.
    Clin Pharmacokinet; 2005 Aug 03; 44(12):1227-46. PubMed ID: 16372822
    [Abstract] [Full Text] [Related]

  • 45. Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: a 6 month phase 3 clinical trial and extension study.
    Tausche AK, Alten R, Dalbeth N, Kopicko J, Fung M, Adler S, Bhakta N, Storgard C, Baumgartner S, Saag K.
    Rheumatology (Oxford); 2017 Dec 01; 56(12):2170-2178. PubMed ID: 29029210
    [Abstract] [Full Text] [Related]

  • 46. How to use warfarin assays in patient management: analysis of 437 warfarin measurements in a clinical setting.
    Lee K, Woo HI, Bang OY, On YK, Kim JS, Lee SY.
    Clin Pharmacokinet; 2015 May 01; 54(5):517-25. PubMed ID: 25466603
    [Abstract] [Full Text] [Related]

  • 47. A physiologically based pharmacokinetic/pharmacodynamic modeling approach for drug-drug interaction evaluation of warfarin enantiomers with sorafenib.
    Wang Z, Xiang X, Liu S, Tang Z, Sun H, Parvez M, Ghim JL, Shin JG, Cai W.
    Drug Metab Pharmacokinet; 2021 Aug 01; 39():100362. PubMed ID: 34242938
    [Abstract] [Full Text] [Related]

  • 48. Kinetic-pharmacodynamic model of warfarin for prothrombin time-international normalized ratio in Japanese patients.
    Hirai T, Aoyama T, Tsuji Y, Itoh T, Matsumoto Y, Iwamoto T.
    Br J Clin Pharmacol; 2024 Mar 01; 90(3):828-836. PubMed ID: 37953511
    [Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. Warfarin withdrawal. Pharmacokinetic-pharmacodynamic considerations.
    Palareti G, Legnani C.
    Clin Pharmacokinet; 1996 Apr 01; 30(4):300-13. PubMed ID: 8983860
    [Abstract] [Full Text] [Related]

  • 51. Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.
    Jiang X, Williams KM, Liauw WS, Ammit AJ, Roufogalis BD, Duke CC, Day RO, McLachlan AJ.
    Br J Clin Pharmacol; 2004 May 01; 57(5):592-9. PubMed ID: 15089812
    [Abstract] [Full Text] [Related]

  • 52. The effect of orlistat on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers.
    Zhi J, Melia AT, Guerciolini R, Koss-Twardy SG, Passe SM, Rakhit A, Sadowski JA.
    J Clin Pharmacol; 1996 Jul 01; 36(7):659-66. PubMed ID: 8844450
    [Abstract] [Full Text] [Related]

  • 53. Cinacalcet does not affect the pharmacokinetics or pharmacodynamics of warfarin.
    Padhi D, Sullivan JT.
    Drugs R D; 2007 Jul 01; 8(2):79-87. PubMed ID: 17324005
    [Abstract] [Full Text] [Related]

  • 54. Phase 1 study of the effect of icosapent ethyl on warfarin pharmacokinetic and anticoagulation parameters.
    Braeckman RA, Stirtan WG, Soni PN.
    Clin Drug Investig; 2014 Jul 01; 34(7):449-56. PubMed ID: 24760401
    [Abstract] [Full Text] [Related]

  • 55. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.
    Aquilante CL, Langaee TY, Lopez LM, Yarandi HN, Tromberg JS, Mohuczy D, Gaston KL, Waddell CD, Chirico MJ, Johnson JA.
    Clin Pharmacol Ther; 2006 Apr 01; 79(4):291-302. PubMed ID: 16580898
    [Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. The effect of multiple doses of donepezil HCl on the pharmacokinetic and pharmacodynamic profile of warfarin.
    Tiseo PJ, Foley K, Friedhoff LT.
    Br J Clin Pharmacol; 1998 Nov 01; 46 Suppl 1(Suppl 1):45-50. PubMed ID: 9839766
    [Abstract] [Full Text] [Related]

  • 58. Evaluation of the Pharmacokinetic Interaction between Venetoclax, a Selective BCL-2 Inhibitor, and Warfarin in Healthy Volunteers.
    Salem AH, Hu B, Freise KJ, Agarwal SK, Sidhu DS, Wong SL.
    Clin Drug Investig; 2017 Mar 01; 37(3):303-309. PubMed ID: 27910036
    [Abstract] [Full Text] [Related]

  • 59. The effects of acetaminophen on pharmacokinetics and pharmacodynamics of warfarin.
    Kwan D, Bartle WR, Walker SE.
    J Clin Pharmacol; 1999 Jan 01; 39(1):68-75. PubMed ID: 9987702
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.